Cargando…

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg

Background. We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Capasso, Nicola, Palladino, Raffaele, Montella, Emma, Pennino, Francesca, Lanzillo, Roberta, Carotenuto, Antonio, Petracca, Maria, Iodice, Rosa, Iovino, Aniello, Aruta, Francesco, Pastore, Viviana, Buonomo, Antonio Riccardo, Zappulo, Emanuela, Gentile, Ivan, Triassi, Maria, Brescia Morra, Vincenzo, Moccia, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766741/
https://www.ncbi.nlm.nih.gov/pubmed/33339402
http://dx.doi.org/10.3390/jcm9124066
_version_ 1783628791358160896
author Capasso, Nicola
Palladino, Raffaele
Montella, Emma
Pennino, Francesca
Lanzillo, Roberta
Carotenuto, Antonio
Petracca, Maria
Iodice, Rosa
Iovino, Aniello
Aruta, Francesco
Pastore, Viviana
Buonomo, Antonio Riccardo
Zappulo, Emanuela
Gentile, Ivan
Triassi, Maria
Brescia Morra, Vincenzo
Moccia, Marcello
author_facet Capasso, Nicola
Palladino, Raffaele
Montella, Emma
Pennino, Francesca
Lanzillo, Roberta
Carotenuto, Antonio
Petracca, Maria
Iodice, Rosa
Iovino, Aniello
Aruta, Francesco
Pastore, Viviana
Buonomo, Antonio Riccardo
Zappulo, Emanuela
Gentile, Ivan
Triassi, Maria
Brescia Morra, Vincenzo
Moccia, Marcello
author_sort Capasso, Nicola
collection PubMed
description Background. We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher’s exact test, chi square test, or McNemar’s test, as appropriate, to evaluate between-group differences. Results. We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (p < 0.001), and similar to the low-risk population (n = 11, 1.3%) (p = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms. Conclusions. MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression.
format Online
Article
Text
id pubmed-7766741
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77667412020-12-28 Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg Capasso, Nicola Palladino, Raffaele Montella, Emma Pennino, Francesca Lanzillo, Roberta Carotenuto, Antonio Petracca, Maria Iodice, Rosa Iovino, Aniello Aruta, Francesco Pastore, Viviana Buonomo, Antonio Riccardo Zappulo, Emanuela Gentile, Ivan Triassi, Maria Brescia Morra, Vincenzo Moccia, Marcello J Clin Med Article Background. We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher’s exact test, chi square test, or McNemar’s test, as appropriate, to evaluate between-group differences. Results. We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (p < 0.001), and similar to the low-risk population (n = 11, 1.3%) (p = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms. Conclusions. MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression. MDPI 2020-12-16 /pmc/articles/PMC7766741/ /pubmed/33339402 http://dx.doi.org/10.3390/jcm9124066 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Capasso, Nicola
Palladino, Raffaele
Montella, Emma
Pennino, Francesca
Lanzillo, Roberta
Carotenuto, Antonio
Petracca, Maria
Iodice, Rosa
Iovino, Aniello
Aruta, Francesco
Pastore, Viviana
Buonomo, Antonio Riccardo
Zappulo, Emanuela
Gentile, Ivan
Triassi, Maria
Brescia Morra, Vincenzo
Moccia, Marcello
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
title Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
title_full Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
title_fullStr Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
title_full_unstemmed Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
title_short Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
title_sort prevalence of sars-cov-2 antibodies in multiple sclerosis: the hidden part of the iceberg
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766741/
https://www.ncbi.nlm.nih.gov/pubmed/33339402
http://dx.doi.org/10.3390/jcm9124066
work_keys_str_mv AT capassonicola prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT palladinoraffaele prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT montellaemma prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT penninofrancesca prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT lanzilloroberta prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT carotenutoantonio prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT petraccamaria prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT iodicerosa prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT iovinoaniello prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT arutafrancesco prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT pastoreviviana prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT buonomoantonioriccardo prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT zappuloemanuela prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT gentileivan prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT triassimaria prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT bresciamorravincenzo prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg
AT mocciamarcello prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg